Which diseases could this technology help treat?

It is expected to contribute to blood purification treatments for intractable diseases such as autoimmune diseases, cardiovascular metabolic disorders, neurodegenerative diseases, and cancer.

How does this technology differ from conventional fibers?

It allows for pore size control up to approximately 1,000nm—more than 50 times larger than before—enabling the selective removal of large-molecular-weight pathogenic substances.

AI News NQ Analysis

Toray Develops Porous Fiber Technology to Adsorb Pathogenic Substances in Intractable Diseases

NQ Score 51/100

AI Summary (NQ-processed)

Toray Industries has developed a technology to precisely control the pore size of PMMA porous fibers up to approximately 1,000nm. This breakthrough enables the selective removal of large-molecular-weight pathogenic substances, offering a new approach for blood purification treatments. The company aims to commercialize this for treating intractable diseases and biopharmaceutical manufacturing.

AI analysis data is not yet available.

Frequently Asked Questions

Q: Which diseases could this technology help treat?: A: It is expected to contribute to blood purification treatments for intractable diseases such as autoimmune diseases, cardiovascular metabolic disorders, neurodegenerative diseases, and cancer.
Q: How does this technology differ from conventional fibers?: A: It allows for pore size control up to approximately 1,000nm—more than 50 times larger than before—enabling the selective removal of large-molecular-weight pathogenic substances.